Khaled El‐Shami

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Sameer A. Parikh, Hagop M. Kantarjian, Aaron D. Schimmer et al. · Clinical Lymphoma Myeloma & Leukemia · 2010 · 85 citations

Inflammation, Molecular Pharmacology, Hematological Malignancy +8

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope

Khaled El‐Shami, Boaz Tirosh, Erez Bar‐Haim et al. · European Journal of Immunology · 1999 · 84 citations

Histocompatibility, Immunology, Immunoediting +21

Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites

Khaled El‐Shami, Amr Abdelaziz Elsaid, Yasser Elkerm · Journal of Clinical Oncology · 2007 · 43 citations

Surgical Oncology, Cancer Management, Pathology +16

Novel breast-tumor-associated MUC1-derived peptides: Characterization in Db−/− × β2 microglobulin (β2m) null mice transgenic for a chimeric HLA-A2.1/Db-β2 microglobulin single chain

Lior Carmon, Khaled El‐Shami, Adrian Paz et al. · International Journal of Cancer · 2000 · 40 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Hhd Mice +15

A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer

Lei Zheng, Barish H. Edil, Kevin C. Soares et al. · Annals of Surgical Oncology · 2014 · 34 citations · Full text

Radiation Oncology, Tumor Immunology, Cancer Immunosurveillance +10